Loargys (pegzilarginase-nbln)
Immedica Pharma
ApprovedFeb 23, 2026
Marketer take
An enzyme therapy for Arginase 1 deficiency used alongside protein restriction, so metabolic geneticists and dietitians are the core audience, and newborn screening and specialist centers drive patient finding.
- Sponsor company
- Immedica Pharma
- Indication
- To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
- Therapeutic area
- Rare disease, Metabolic
- Event
- FDA approval
- Date
- Feb 23, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?